Current Frontline Treatment Approaches in EGFR+ Advanced NSCLC

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, review current standards of care for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC). They discuss how mutation subtype, disease burden, and patient-specific factors influence frontline therapy selection. The conversation also frames how newer combination strategies are being integrated alongside established EGFR TKIs.